Aadi bioscience announces poster presentations at the north american neuroendocrine tumor society (nanets) 2023 multidisciplinary net medical symposium

Los angeles , oct. 5, 2023 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mtor pathway alterations, today announced that two posters will be presented at the upcoming north american neuroendocrine tumor society (nanets) multidisciplinary net medical symposium, taking place october 4-6, 2023, in montreal, canada.  details of the poster presentations are below: title: "phase 2 study of nab-sirolimus in patients with well-differentiated and advanced or metastatic neuroendocrine tumors of the gastrointestinal tract, lung, or pancreas" date/time:  thursday, october 5, 2023, 5:15 pm – 7:00 pm edt presentation location: poster gallery location, square dorchester presenter: scott paulson, md authors: michael j.
AADI Ratings Summary
AADI Quant Ranking